ASMB Assembly Biosciences

Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison, AO, MD, Chief Executive Officer and President will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 2pm ET.

A live webcast and replay will be available on the Events & Presentations page in the Investors section of the company's website at .  

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP-compliant banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit .

Contacts

Assembly Biosciences, Inc.

Investors:

Lauren Glaser

(415) 521-3828

EN
19/02/2020

Underlying

ASMBAssembly Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assembly Biosciences

 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Positive Interim Results from Phase 1b Cl...

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shed...

December 8, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Reports Third Quarter 2025 Financial Results and ...

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates – Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly ora...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generati...

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® – Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for its next-generation investigational capsid assem...

November 7, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Announces Upcoming Investor Conference Participat...

Assembly Biosciences Announces Upcoming Investor Conference Participation SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor conferences. H.C. Wainwright Liver Disease Virtual ConferenceAnuj Gaggar, MD, PhD, chief medical officer, will present in a pre-recorded fireside chat that will be available on demand during the H.C. Wainwright Liver Disease Vir...

October 14, 2025 1 EN
 PRESS RELEASE
Free
ASMB Assembly Biosci...

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-P...

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe – Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes –  – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – Interim data evaluating a m...

October 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch